UY32308A - Nucleótidos uracil ciclopropílicos - Google Patents

Nucleótidos uracil ciclopropílicos

Info

Publication number
UY32308A
UY32308A UY0001032308A UY32308A UY32308A UY 32308 A UY32308 A UY 32308A UY 0001032308 A UY0001032308 A UY 0001032308A UY 32308 A UY32308 A UY 32308A UY 32308 A UY32308 A UY 32308A
Authority
UY
Uruguay
Prior art keywords
benzyl
alkyl
hydrogen
cyclopropyll
uracil
Prior art date
Application number
UY0001032308A
Other languages
English (en)
Inventor
Jonckers Tim Hugo Maria
Raboisson Pierre Jean-Marie
Van Hoof Steven Maurice Paula
Vandekerckhove Leen Anna Maria
Vandyck Koen
Original Assignee
Medivir Ab
Centocor Ortho Biotech Products L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab, Centocor Ortho Biotech Products L P filed Critical Medivir Ab
Publication of UY32308A publication Critical patent/UY32308A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de fórmula I: que incluyen cualquier estereoisómero posible de los mismo, donde: R1 es hidrógeno o halo; R4 es un éster de monofosfato, difosfato o trifosfato; o R4 es un grupo de fórmula R7 e fenilo opcionalmente sustituido; naftilo, indolilo o N-alquiloxi C1-C6-carbonilindolilo; R8 es hidrógeno, alquilo C1-C6, bencilo; R8´ es hidrógeno, alquilo C1-C6, bencilo; o R8 y R8´ conjuntamente con el átomo de carbono al cual están unidos forman cicloalquilo C3-C7; R9 es alquilo C1-C10, bencilo, o fenilo opcionalmente sustituido; o una sal o solvato de los mismos. formulaciones farmacéuticas y el uso de compuestos I como inhibidores de HCV
UY0001032308A 2008-12-08 2009-12-08 Nucleótidos uracil ciclopropílicos UY32308A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08171006 2008-12-08

Publications (1)

Publication Number Publication Date
UY32308A true UY32308A (es) 2010-06-30

Family

ID=40852521

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032308A UY32308A (es) 2008-12-08 2009-12-08 Nucleótidos uracil ciclopropílicos

Country Status (21)

Country Link
US (1) US8399429B2 (es)
EP (1) EP2373671B1 (es)
JP (1) JP5683480B2 (es)
KR (1) KR20110104000A (es)
CN (1) CN102256991B (es)
AP (1) AP2011005717A0 (es)
AR (1) AR074504A1 (es)
AU (1) AU2009326125B2 (es)
BR (1) BRPI0922681A2 (es)
CA (1) CA2745523C (es)
CL (1) CL2011001364A1 (es)
EA (1) EA020244B1 (es)
ES (1) ES2525007T3 (es)
IL (1) IL212897A (es)
MX (1) MX2011006023A (es)
PA (1) PA8852101A1 (es)
SG (1) SG171973A1 (es)
TW (1) TW201036989A (es)
UY (1) UY32308A (es)
WO (1) WO2010066699A1 (es)
ZA (1) ZA201104231B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3027B1 (ar) * 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
AR091156A1 (es) 2012-05-25 2015-01-14 Jansen R & D Ireland Nucleosidos de espirooxetano de uracilo
EP2920192B1 (en) * 2012-11-16 2017-02-22 University College Cardiff Consultants Limited Process for preparing nucleoside prodrugs
AU2014225052B2 (en) * 2013-03-08 2016-11-10 Nanjing Sanhome Pharmaceutical Co., Ltd. Novel nucleoside phosphoramidate compound and use thereof
CN103848876B (zh) * 2013-03-25 2016-05-11 安徽贝克联合制药有限公司 一种核苷磷酰胺前药及其制备方法和其应用
BR112015025766A2 (pt) 2013-04-12 2017-10-17 Achillion Pharmaceuticals Inc derivado de nucleosídeo altamente ativo para o tratamento de hcv
CN105348342B (zh) * 2014-09-30 2018-09-21 南京正大天晴制药有限公司 核苷氨基磷酸酯化合物及药物组合物和用途
WO2016073756A1 (en) * 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
CN105801646B (zh) * 2014-12-31 2019-08-16 浙江大德药业集团有限公司 炔基取代的核苷氨基磷酸酯
WO2016134053A1 (en) * 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
KR102363946B1 (ko) 2015-03-06 2022-02-17 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
EP3344642A1 (en) 2015-09-02 2018-07-11 AbbVie Inc. Anti-viral tetrahydrofurane derivatives
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP4088725A1 (en) 2016-09-07 2022-11-16 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family
UA127407C2 (uk) 2017-02-01 2023-08-16 Атеа Фармасеутікалс, Інк. Гемісульфатна сіль нуклеотиду для лікування спричиненого вірусом гепатиту с захворювання
JP2021521118A (ja) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド 肝硬変を伴うｈｃｖ感染患者の治療
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
PT727419E (pt) 1992-12-29 2002-08-30 Abbott Lab Compostos intermediarios para a preparacao de inibidores da protease retroviral
US20010021509A1 (en) * 1997-10-23 2001-09-13 Sathe Ganesh Madhusudan cDNA clone HNEAA81 that encodes a human 7-transmembrane receptor
ES2469569T3 (es) * 2002-06-28 2014-06-18 Idenix Pharmaceuticals, Inc. Prof�rmacos de nucle�sidos modificados en 2' y 3' para el tratamiento de infecciones de Flaviviridae
EP1653976A4 (en) * 2003-02-19 2009-07-29 Univ Yale ANTIVIRAL NUCLEOSIDE ANALOGUES AND METHODS FOR TREATING VIRAL INFECTIONS, IN PARTICULAR HIV INFECTIONS
EP1628685B1 (en) * 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US8802840B2 (en) * 2005-03-08 2014-08-12 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
AP2009004812A0 (en) 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor

Also Published As

Publication number Publication date
EP2373671B1 (en) 2014-09-10
US20110230436A1 (en) 2011-09-22
AU2009326125B2 (en) 2015-03-12
ES2525007T3 (es) 2014-12-17
CN102256991B (zh) 2015-08-12
AU2009326125A1 (en) 2010-06-17
EP2373671A1 (en) 2011-10-12
JP5683480B2 (ja) 2015-03-11
US8399429B2 (en) 2013-03-19
AR074504A1 (es) 2011-01-19
JP2012510980A (ja) 2012-05-17
CA2745523A1 (en) 2010-06-17
PA8852101A1 (es) 2010-07-27
IL212897A0 (en) 2011-07-31
TW201036989A (en) 2010-10-16
CA2745523C (en) 2017-07-04
ZA201104231B (en) 2012-11-28
EA201170780A1 (ru) 2011-12-30
SG171973A1 (en) 2011-07-28
KR20110104000A (ko) 2011-09-21
CL2011001364A1 (es) 2011-09-23
BRPI0922681A2 (pt) 2016-01-05
WO2010066699A1 (en) 2010-06-17
CN102256991A (zh) 2011-11-23
MX2011006023A (es) 2011-06-28
EA020244B1 (ru) 2014-09-30
AP2011005717A0 (en) 2011-06-30
IL212897A (en) 2013-12-31

Similar Documents

Publication Publication Date Title
UY32308A (es) Nucleótidos uracil ciclopropílicos
CO6440533A2 (es) Nucleósidos espiro oxetánicos uracílicos
CO6321255A2 (es) "inhibidores de ciclopropil polimerasa"
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
ECSP109932A (es) Compuestos de biciclolactama sustituida
UY32759A (es) Inhibidores del virus de la hepatitis c
CO6210729A2 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico
AR082968A1 (es) Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto
AR072803A1 (es) Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes
AR080249A1 (es) Compuestos en calidad de antagonistas de bradiquinina-b1
BR112017007784A2 (pt) aperfeiçoamentos em ou relacionados a compostos orgânicos
AR073037A1 (es) Derivados de enfumafungina, utiles en la inhibicionde (1,3)-beta-d-glucano sintasa
AR088414A1 (es) Derivados sustituidos de indol
AR085542A1 (es) Compuestos de azaespirodecanona como inhibidores de hsl
AR079267A1 (es) Derivados del tipo hexahidrociclopenta(b)pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR074514A1 (es) Derivados de morfina-6-glucuronido, su preparacion y su aplicacion en terapeutica
AR112803A2 (es) Derivados de piperazina como moduladores de piruvato quinasa m2 (pkm2)
AR079265A1 (es) Derivados de azabiciclo(3.1.0)hex-2-ilo, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
TH112183B (th) สารยับยั้งไซโคลโพรพิล พอลิเมอเรส
UY31262A1 (es) Compuestos de biciclolactama sustituida
CO6280059A1 (es) Nuevos derivados de azabiciclos (3.2.0) hept-3-ilo su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY32895A (es) Derivados acetilénicos de 5-fenilpirazolopiridina, su preparación y su aplicación terapéutica
CO6382159A2 (es) Derivados bicíclicos de morfina-6-glucurónido, su preparación y su aplicación en terapéuticaqq
CU20100017A7 (es) Compuestos de biciclolactama sustituida
AR079266A1 (es) Derivados de azabiciclo[3.2.0]hept-6ilo, procedimiento de preparacion de los mismos, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer.